Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former Generic Industry Exec Who Went Undercover For DOJ No Longer Debarred

Executive Summary

US FDA chief scientist said former exec, who was part of the generic drug scandal, deserves special termination of 1993 debarment due to his 'substantial assistance' to the DOJ in its investigations of others. Office of Regulatory Affairs wanted to deny his petition.

You may also be interested in...



US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree

Jacqueline O’Shaughnessy takes over as acting chief scientist following Denise Hinton’s move to the surgeon general’s office; Hinton previously had been tapped by acting commissioner Janet Woodcock to make a final decision on the accelerated approval status of Covis' preterm birth prevention drug Makena.

Generic Drug Industry Scandal: Convicted FDA Reviewer Is Freed From Debarment

Twenty-five years after he pled guilty to taking payments from companies, former FDA review chemist David Brancato gets FDA to terminate his debarment; several industry execs won terminations years ago.

EX-PARKE-DAVIS RESEARCH SCIENTIST BOTZOLAKIS CHARGED WITH CONSPIRACY

EX-PARKE-DAVIS RESEARCH SCIENTIST BOTZOLAKIS CHARGED WITH CONSPIRACY to transport property stolen from Parke-Davis into interstate commerce. The criminal information against John Botzolakis is one of four new sets of charges stemming from the the probe of the generic drug industry by the Maryland U.S. District Attorney. The criminal informations were disclosed Sept. 6. According to a release from the District Attorney's office, Botzolakis is charged in criminal information with accepting a total of $ 14,000 from a representative of American Therapeutics Inc. for "formulas and other information regarding two Parke-Davis drugs, prazepam [Centrax] and erythromycin [Eryc]." Botzolakis is the first employee of a brandname pharmaceutical company to be implicated in the Maryland District Attorney's investigation. Botzolakis began working for Parke-Davis in 1984 and left in July 1991. The company would not comment on the specifics of his departure. The firm said it is "cooperating with the government fully" and that civil litigation against Botzolakis is "under consideration." In potentially related charges, former ATI VP Sanyasi Kalidindi has been charged with "participating in ATI's filing of a false application with FDA for approval to manufacture and market erythromycin." The district attorney's press release says that ATI's application "misrepresented the size, manufacturing process, and time and place of manufacture of the research and development batch of the product upon which the application was based." ATI has previously been convicted of making unlawful payments to FDA officials regarding this application and was fined $ 1 mil. in Oct. 1990 ("The Pink Sheet" Oct. 22, 1990, p. 10). In June 1989, Mylan initiated a suit against two former FDA generic division chemists and several pharmaceutical companies, including ATI and Vitarine, alleging that FDA was giving preferential treatment to those companies in the approval of ANDAs. Prazepam was among the 23 drugs that Mylan said was receiving "discriminatory" treatment in the approval process. That suit is still pending in D.C. District Court. Bolar Manager of Product Development Juan Rodriguez was charged with "attempting to obstruct an FDA investigation of Bolar." The U.S. Attorney's office alleges that Rodriguez "rewrote a notebook to include false information regarding his research and development activities at Bolar" that he turned over to FDA investigators. Three Bolar employees -- Regulatory Affairs Director Susan Long, Regulatory Affairs Manager Gloria Schetlick and R&D Lab Director Gena Finelli -- have already been convicted of these charges and await sentencing. The fourth criminal information disclosed by the district attorney charges former Vitarine VP Operations John Bushlow. Announcement of criminal charges against him came on the same day former Vitarine VP R&D Steven Colton, PhD, was sentenced to 27 months in prison for making false statments to FDA in connection with six generic ANDAs (see following T&G). The release states that Bushlow, Kalidindi, and Rodriguez are cooperating with the government investigations. All four suspects face a maximum penalty of five years incarceration and/or a $ 250,000 fine, with the exception of Bushlow, who faces a maximum three year and/or $ 250,000 sentence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel